Related Experiment Video
Updated: Jan 24, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Pazopanib in advanced soft tissue sarcomas
Alex T J Lee1,2, Robin L Jones2,3, Paul H Huang1
11Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Abstract:
Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors, preclinical work indicates that pazopanib exerts an anticancer effect through the inhibition of both angiogenic and oncogenic signaling pathways. Following the establishment of optimal dosing and safety profiles in early phase studies and approval for the treatment of advanced renal cell carcinoma, pazopanib was investigated in STS. A landmark phase III randomized study demonstrated improved progression-free survival with pazopanib compared to that with placebo in pretreated patients with STS of various subtypes. The efficacy of pazopanib in specific STS subtypes has been further described in real-world-based case series in both mixed and subtype-specific STS cohorts. At present, there are no clinically validated predictive biomarkers for use in selecting patients with advanced STS for pazopanib therapy, limiting the clinical effectiveness and cost-effectiveness of the drug. In this review, we summarize the preclinical and clinical data for pazopanib, outline the evidence base for its effect in STS and explore reported studies that have investigated putative biomarkers.
Insights
Pazopanib improves progression-free survival in patients with advanced soft tissue sarcoma (STS). This review summarizes pazopanib
Area of Science:
- Oncology
- Pharmacology
- Medical Research
Background:
- Pazopanib is a tyrosine kinase inhibitor approved for soft tissue sarcoma (STS).
- It targets vascular endothelial growth factor receptors, inhibiting angiogenic and oncogenic pathways.
- Pazopanib is also approved for advanced renal cell carcinoma.
Purpose of the Study:
- To review preclinical and clinical data for pazopanib in STS.
- To outline the evidence for pazopanib's efficacy in various STS subtypes.
- To explore potential biomarkers for pazopanib therapy in advanced STS.
Main Methods:
- Review of preclinical studies on pazopanib's mechanism of action.
- Analysis of Phase III randomized trial data for pazopanib in STS.
- Examination of real-world case series on pazopanib's efficacy in STS cohorts.
Main Results:
- Pazopanib demonstrated improved progression-free survival versus placebo in pretreated STS patients.
- Efficacy has been described in mixed and subtype-specific STS cohorts.
- No validated predictive biomarkers currently exist for selecting patients for pazopanib therapy.
Conclusions:
- Pazopanib is an effective treatment for advanced STS across multiple subtypes.
- Lack of predictive biomarkers limits optimal patient selection and cost-effectiveness.
- Further research into biomarkers is needed to enhance pazopanib's clinical utility.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Extraction: Advanced Methods
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Tissues

